Search Results for “ diabetes” – Page 38 – media

Study shows link between obesity and adverse postoperative outcomes

In the United States, almost 74% of adults age 20 and older have overweight or obesity, and of that number almost 42% have obesity. Not only are overweight and obesity complex and serious diseases, but clinicians and researchers are continuing to learn how they can impact health outcomes – from heart and musculoskeletal health to risk for disease, including cancer. New research published in the journal SURGERY shows that obesity is also associated with increased risk of complications following surgery, including infection, blood clots, and kidney complications. “We need to continue to recognize that overweight and obesity can have medical impacts that aren’t limited to heart disease and diabetes and liver failure. They can also make recovery from surgery harder, and these data can inform the conversation happening at a broader public health level addressing obesity.” Robert Meguid, MD, MPH, researcher, professor of cardiothoracic surgery in the ...
- Source: drugdu
- 179
- May 5, 2023
Long siesta-takers have higher BMIs and more likely to have metabolic syndrome

Through data-analysis, researchers found that people taking long siestas had higher body mass indexes and were more likely to have metabolic syndrome than those who did not take siestas. It is a common custom in some countries for individuals to take a siesta or midday nap. Sleeping during the middle of the day has the potential to affect sleep quality, cognitive function, and metabolic processes. However, the relationship between siestas and metabolic health is not well understood. A new study led by investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, assessed more than 3,000 adults from a Mediterranean population, examining the relationship of siestas and siesta duration with obesity and metabolic syndrome. The researchers found that those who took siestas of 30 minutes or longer (long siestas) were more likely to have a higher body mass index, higher blood pressure, and ...
- Source: drugdu
- 140
- May 1, 2023
Doctors watching for more cases after mysterious cluster of brain infections strikes kids in southern Nevada

Disease detectives with the US Centers for Disease Control and Prevention are investigating a cluster of rare and serious brain abscesses in kids in and around Las Vegas, Nevada, and doctors from other parts of the country say they may be seeing a rise in cases, too. In 2022, the number of brain abscesses in kids tripled in Nevada, rising from an average of four to five a year to 18. “In my 20 years’ experience, I’ve never seen anything like it,” said Dr. Taryn Bragg, an associate professor at the University of Utah who treated the cases. Pediatric neurosurgeons like Bragg are rare. She is the only one for the entire state of Nevada, and because she treated all the cases, she was the first to notice the pattern and to alert local public health officials. “After March of 2022, there was just a ...
- Source: drugdu
- 138
- May 1, 2023
Roche’s Genentech opens up the world with new ad for Vabysmo

Adults facing wet age-related macular degeneration (AMD) and diabetic macular edema (DME) fear their world getting smaller due to loss of eyesight. Roche’s Genentech addresses that issue head-on in its first DTC ad for Vabysmo. The new “Open up your world with Vabysmo” campaign was developed with input from patients, caregivers, advocacy groups and the retinal community impacted by wet AMD and DME. “One of the critical insights was that many of these patients felt when they were losing their vision it made their world feel really small—they didn’t get to go out as much, they weren’t necessarily doing their daily activities of living because they felt like they were losing their sight and therefore inhibiting that ability,” Jennifer Kim, Genentech’s vice president and head of ophthalmology, said. “So that’s how we developed that concept around open up your world. The idea of the campaign is ...
- Source: drugdu
- 139
- May 1, 2023
Merck results beat expectations despite a big drop in sales of Covid antiviral treatment

Merck on Thursday reported first-quarter revenue and adjusted earnings that topped Wall Street’s expectations, despite a steep drop in sales of its Covid antiviral treatment molnupiravir. Sales of molnupiravir plunged to $392 million during the period, down 88% from the $3.2 billion reported for the first quarter of 2022. Merck said the decrease is primarily the result of lower sales in the U.S., U.K., Japan and Australia. The company reported total revenue of $14.5 billion for the quarter, down 9% from a year earlier. But excluding the Covid drug, Merck said its revenue grew 11%. Here’s what Merck reported compared with Wall Street’s expectations, based on a survey of analysts by Refinitiv: Earnings per share: $1.40 adjusted, vs. $1.32 expected Revenue: $14.49 billion, vs. $13.78 billion expected Merck’s stock closed more than 1% higher Thursday. The shares are up more than 3% for ...
- Source: drugdu
- 127
- May 1, 2023
Sanofi, Regeneron unveil ‘blow-out’ smoker’s lung drug data

March 23 (Reuters) – Sanofi’s (SASY.PA) asthma drug Dupixent met all targets in a trial to treat “smoker’s lung”, potentially adding billions to the French drugmaker’s growth prospects, but also underscoring a heavy reliance on its bestseller. In a late stage trial Dupixent, jointly developed with Regeneron (REGN.O), led to a 30% reduction in moderate or severe acute exacerbations of chronic obstructive pulmonary disease (COPD), a potentially deadly disease marked by progressive lung function decline. Shares in Sanofi and Regeneron surged after they said in a joint statement on Thursday a Phase III trial involving 939 current or former smokers also showed improvements in lung function, quality of life and respiratory symptoms. The French group’s stock was up 5.2% at 1205 GMT, reaching a seven-month high and far outperforming the STOXX Europe 600 Health Care index (.SXDP), which was little changed. Regeneron jumped 8.6% in U.S. ...
- Source: drugdu
- 179
- April 28, 2023
Eli Lilly to sell low blood sugar drug Baqsimi to Amphastar in deal worth over $1bn

The drug is available in 27 markets, with worldwide sales totalling over $139m in 2022. Eli Lilly will sell its low blood sugar drug Baqsimi to Amphastar Pharmaceuticals in a deal worth over $1bn, the two companies announced. Under the terms of the definitive agreement, Amphastar will pay Lilly $500m at closing and an additional $125m after one year, with Lilly also eligible to receive sales-based milestone payments of up to $450m. Baqsimi is the first and only nasally administered glucagon to treat severe hypoglycaemia – very low blood sugar – in diabetes patients aged four years and above. Classed as a diabetic emergency, severe hypoglycaemia is a complication that can occur in diabetes patients who take insulin and certain anti-diabetic tablets. The condition is characterised by altered mental or physical functioning, including confusion and disorientation, convulsions, loss of consciousness and coma. Lilly launched Baqsimi ...
- Source: drugdu
- 168
- April 28, 2023
High-protein diet counters adaptive thermogenesis in prediabetic individuals

The high rate of obesity has become a growing problem in the modern world. Obesity is associated with the incidence of several comorbidities, such as cardiovascular diseases and type 2 diabetes. Despite weight loss being considered the most important remedy for obesity, long-term weight maintenance is also important. Background Metabolic adaptation, i.e., adaptive thermogenesis (AT), could be the key factor preventing long-term weight-loss maintenance. AT causes a decrease in energy expenditure, which is significantly more than the predictions based on reductions in fat mass (FM) or fat-free mass (FFM). Energy expenditure adaptations have been found to last multiple years after a weight loss period. Therefore, after weight loss, a reduction in AT is extremely important for long-term weight loss maintenance. Some factors have been identified to reduce AT, such as physical activity, cold-induced brown adipose tissue activation, tea catechins, and capsaicinoids. Furthermore, high protein (HP) intake was also ...
- Source: drugdu
- 142
- April 27, 2023
Arterial stiffness may be a novel risk factor for childhood and adolescent metabolic disease

Arterial stiffness may be a novel risk factor for metabolic syndrome in teens, a paper published in the American Journal of Physiology-Heart and Circulatory Physiology concludes. The study was conducted in collaboration between the University of Bristol in the UK, the University of Exeter in the UK, and the University of Eastern Finland. The presence of any three of high blood pressure, high trunk fat mass, high fasting glucose, high fasting triglyceride and low fasting high-density lipoprotein cholesterol describes metabolic syndrome. Arterial stiffness in adolescents measured with carotid-femoral pulse wave velocity may potentially cause metabolic syndrome in young adulthood via an increase in fasting insulin resistance and low-density lipoprotein cholesterol. Image Credit: Andrew Agbaje. The World Health Organization describes metabolic syndrome as the constellation of three or more of the following: abdominal obesity, insulin resistance, hypertension, and hyperlipidemia. The prevalence of metabolic syndrome in US middle-aged adults is 30%, ...
- Source: drugdu
- 109
- April 27, 2023
Seasonal Variation in Thyroid Hormone TSH May Lead to Overprescribing

By Miriam E. Tucker Seasonal variation in one of the hormones used to monitor thyroid function could in turn lead to false diagnoses of subclinical hypothyroidism and unnecessary prescriptions of levothyroxine, says Yale clinical chemist Joe M. El-Khoury, PhD. He says a Japanese study in more than 7000 healthy individuals showed that thyrotropin-stimulating hormone (TSH) varies widely throughout the seasons, peaking in the northern hemisphere’s winter months (January to February) with its low in the summer months (June to August); that paper was published last year in the Journal of the Endocrine Society. But free thyroxine (FT4) levels in the Japanese population remained relatively stable, he writes in a letter recently published in Clinical Chemistry. “If you end up with a mildly elevated TSH result and a normal FT4, try getting retested 2-3 months later to make sure this is not a seasonal artifact or transient increase before prescribing/taking levothyroxine unnecessarily,” advises El-Khoury, who is director of Yale University’s Clinical Chemistry Laboratory, ...
- Source: drugdu
- 130
- April 26, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.